Selectis Health Audit Committee Member Resigns, Raising Governance Concerns
GBCS has more than doubled off its 52-week low of $0.405 on light trading volume (0.4× avg).
Summary
David Furstenberg has resigned from Selectis Health's Board of Directors and Audit Committee, effective March 30, 2026, with no reason for his departure disclosed. This resignation, particularly from a key oversight committee, raises questions about corporate governance and potential internal issues at the company. It follows closely on the heels of the board's 'no recommendation' regarding Black Pearl Equities' $5.05 per share cash offer, adding to the narrative of potential internal dynamics and strategic uncertainty. Traders will likely view this as a negative signal and monitor for further board changes or explanations.
At the time of this announcement, GBCS was trading at $4.20 on OTC in the Life Sciences sector, with a market capitalization of approximately $12.9M. The 52-week trading range was $0.41 to $6.25. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.